Drugs  	Drugs  	 NNS	O
and  	and  	 CC	O
toxins-associated  	toxins-associated  	 JJ	O
pulmonary  	pulmonary  	 JJ	B-NP
arterial  	arterial  	 JJ	I-NP
hypertension 	hypertension 	 NN	I-NP
:  	:  	 :	O
lessons  	lessons  	 NNS	O
learned  	learned  	 VBN	O
and  	and  	 CC	O
challenges  	challenges  	 NNS	O
ahead  	ahead  	 RB	O
Since  	Since  	 IN	O
the  	the  	 DT	O
identification  	identification  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
link  	link  	 NN	O
between  	between  	 IN	O
pulmonary  	pulmonary  	 FW	B-NP
arterial  	arterial  	 FW	I-NP
hypertension  	hypertension  	 FW	I-NP
( 	( 	 -LRB-	O
PAH 	PAH 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
exposure  	exposure  	 NN	O
to  	to  	 TO	O
certain  	certain  	 JJ	O
drugs  	drugs  	 NNS	O
and  	and  	 CC	O
toxins  	toxins  	 VBP	O
nearly  	nearly  	 RB	O
fifty  	fifty  	 JJ	O
years  	years  	 NNS	O
ago 	ago 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
expanding  	expanding  	 VBG	O
landscape  	landscape  	 NN	O
of  	of  	 IN	O
available  	available  	 JJ	O
pharmaceuticals  	pharmaceuticals  	 NNS	O
and  	and  	 CC	O
illicit  	illicit  	 JJ	O
drugs  	drugs  	 NNS	O
is  	is  	 VBZ	O
further  	further  	 RB	O
fueling  	fueling  	 VBG	O
this  	this  	 DT	O
association 	association 	 NN	O
.  	.  	 .	O
While  	While  	 IN	O
some  	some  	 DT	O
causative  	causative  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
in  	in  	 IN	O
drugs  	drugs  	 NNS	O
and  	and  	 CC	O
toxins  	toxins  	 VB	O
associated  	associated  	 VBN	B-NP
PAH  	PAH  	 NNP	I-NP
( 	( 	 -LRB-	O
D 	D 	 NNP	O
& 	& 	 CC	O
T-APAH 	T-APAH 	 NNP	B-NP
)  	)  	 -RRB-	O
have  	have  	 VBP	O
been  	been  	 VBN	O
identified 	identified 	 VBN	O
,  	,  	 ,	O
little  	little  	 RB	O
is  	is  	 VBZ	O
known  	known  	 VBN	O
about  	about  	 IN	O
the  	the  	 DT	O
exact  	exact  	 JJ	O
biology  	biology  	 NN	B-NP
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
implications  	implications  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
disease 	disease 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
review 	review 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
discuss  	discuss  	 VB	O
the  	the  	 DT	O
historical  	historical  	 JJ	B-NP
evidence  	evidence  	 NN	I-NP
that  	that  	 WDT	O
links  	links  	 VBZ	O
PAH  	PAH  	 NNP	B-NP
with  	with  	 IN	O
exposure  	exposure  	 NN	O
to  	to  	 TO	O
anorexinogens 	anorexinogens 	 VB	O
,  	,  	 ,	O
cocaine 	cocaine 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
methamphetamines  	methamphetamines  	 NNS	B-NP
and  	and  	 CC	O
concentrate  	concentrate  	 VB	O
on  	on  	 IN	O
what  	what  	 WP	O
is  	is  	 VBZ	O
known  	known  	 VBN	O
about  	about  	 IN	O
potential  	potential  	 JJ	B-NP
pathogenesis 	pathogenesis 	 NN	I-NP
,  	,  	 ,	O
clinical  	clinical  	 JJ	B-NP
manifestations 	manifestations 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
current  	current  	 JJ	O
management 	management 	 NN	O
.  	.  	 .	O
We  	We  	 PRP	O
conclude  	conclude  	 VBP	O
that  	that  	 IN	O
future  	future  	 JJ	O
research  	research  	 NN	O
should  	should  	 MD	O
focus  	focus  	 VB	O
on  	on  	 IN	O
studies  	studies  	 NNS	O
looking  	looking  	 VBG	O
at  	at  	 IN	O
clinical  	clinical  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
and  	and  	 CC	O
susceptibility  	susceptibility  	 JJ	B-NP
factors 	factors 	 NNS	I-NP
.  	.  	 .	O
